10 Oversold Biotech Stocks to Buy Now

6. NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS)

Relative Strength Index (RSI): 37.46

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) is a late-stage biopharmaceutical company that develops therapies to enhance patient care in populations with metabolic diseases. It is creating an oral low-dose inhibitor of cholesteryl ester transfer protein (CETP), anacetrapib. Due to a series of encouraging reports on the progress of its drug pipeline, analysts say the stock has been soaring and is still among the top 52-week high stocks to purchase.

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) declared in 2024 that three Phase 3 trials of its main drugs had yielded positive topline outcomes. With a fixed-dose combination, TANDEM reduced LDL-C by 49%; BROOKLYN accomplished 36%; and BROADWAY demonstrated 33% LDL-C reduction and 21% MACE reduction. With $835 million on the balance sheet at the end of 2024, the corporation has enough cash on hand to expedite the development of the three programs.

By increasing production and expanding its inventory, NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) is preparing for high commercial demand. A commercialization agreement with Menarini in Europe strengthens revenue potential and validates its efforts even further. The company is confident in Obicetrapib’s long-term future because it has obtained patent protection through 2043. By building production capacity, it is currently concentrating on commercial preparedness, which enhances its portfolio of intellectual property and long-term revenue potential.